AiCuris has a broad R&D portfolio consisting of:
PREVYMIS™ (letermovir) approved for prophylaxis of CMV reactivation and disease in CMV-seropositive hematopoietic stem cell transplant recipients. Phase 3 trial in solid organ transplant recipients ongoing.
AIC316 (pritelivir), a helicase-primase inhibitor, being developed to treat herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) infections. Phase 2 trial in labial herpes (topical indication) completed; Phase 2 trial in acyclovir resistant infections ongoing.
AIC649, a novel biological immune modulator that aims to provide patients with a curative treatment for hepatitis B virus (HBV) with positive Phase 1 clinical trial results.
AIC499, resistance-breaker for Gram- negative bacterial infections currently in Phase 1.
Additional research projects in virology and bacteriology sustain a continuous and balanced pipeline of innovative drug candidates.